It has been confirmed effective but imperfect for the decision of offering immunotherapy because it is insufficient to explain the benefits of patients with a PD-L1 tumor proportion score (TPS) <50%, which might be owing to the heterogeneity of tumor microenvironments and other technical factors (Shen and Zhao, 2018). Here, CD274 is linked to neoplasm.